Organovo, already leading the way in 3D bioprinting with exVive3D brand human liver tissue now available and kidney tissue to follow next year, has just announced a Research Collaboration Agreement with L'Oréal USA Products, Inc., one of the largest skincare companies in the world. The two companies will work together toward developing 3D printed skin, each providing impressive technology: Organovo's NovoGen Bioprinter and L'Oréal's skin cell technology. The agreement covers three phases of work, with specific criteria in place to determine whether the collaboration will continue upon each phase's completion. The bioprinted skin tissue could represent a huge step forward in development and testing of drugs and other products. For more specific details on the collaborative effort, read the full article: http://3dprint.com/56475/loreal-organovo-skin-research/